Boryung Signs CDMO Agreement with Cheplapharm for Schizophrenia Treatment "Zyprexa"

First Global Production Agreement for Oral Medication
Supply to Up to 46 Countries Starting Next Year

On July 17, Boryung announced that it has signed a Contract Development and Manufacturing Organization (CDMO) agreement with the global pharmaceutical company Cheplapharm for the global supply of the schizophrenia treatment "Zyprexa" (Zyprexa®, active ingredient: olanzapine).

Boryung CSO Sungjin Kim (left) and Cheplapharm Vice President Artem Gevorkian are signing at the contract signing ceremony for the "Contract Development and Manufacturing Organization (CDMO) Agreement for Global Supply of Zaiprex Tablets" held on the 15th at Boryung Yesan Campus. Boryung

Under this agreement, starting from the end of next year, Boryung will supply Zyprexa to Cheplapharm for distribution in up to 46 countries, including those in Europe and North America.

Cheplapharm is a global pharmaceutical company based in Germany and Switzerland, supplying medicines to more than 145 countries worldwide, and recorded sales of approximately KRW 2.4 trillion last year. In 2023, Cheplapharm further strengthened its position in the field of neuropsychiatric treatments by acquiring the global rights to Zyprexa, excluding Korea, from the global pharmaceutical company Eli Lilly.

In 2021, Boryung acquired the domestic rights to Zyprexa from Lilly through a Legacy Brands Acquisition (LBA) method. After completing global technology transfer and quality equivalence verification, the company transitioned production to its own facilities last year. Centered on the Yesan Campus in Chungnam, Boryung has secured stable production capabilities for Zyprexa and is now set to begin global supply in earnest.

All products will be manufactured at Boryung's Yesan Campus. In 2023, the Yesan Campus obtained EU-GMP certification from the European Medicines Agency (EMA) for its cytotoxic injectable anticancer drug production facilities. The campus is currently preparing to obtain EU-GMP certification for oral formulations and cGMP certification from the U.S. Food and Drug Administration (FDA) for the Zyprexa production line.

This contract marks Boryung's first global CDMO agreement for an oral formulation. The company stated, "This is a turning point that expands our CDMO capabilities, previously centered on injectable anticancer drugs through last year's agreement with Lotus in Taiwan, to include oral formulations. It also demonstrates the potential for global expansion based on our own production capabilities."

Sungjin Kim, Boryung's Chief Strategy Officer (CSO), emphasized, "This agreement is significant because Boryung has been recognized by a global pharmaceutical company for both its production capabilities for original blockbuster products and its ability to obtain approval and supply in 46 countries. Based on this collaboration, we will continue to create opportunities for global expansion of our CDMO business, including further cooperation with Cheplapharm."